<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00339833</url>
  </required_header>
  <id_info>
    <org_study_id>999903121</org_study_id>
    <secondary_id>03-DK-N121</secondary_id>
    <secondary_id>03-DK-N121</secondary_id>
    <nct_id>NCT00339833</nct_id>
  </id_info>
  <brief_title>The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers</brief_title>
  <official_title>The Effect of Salsalate Treatment on Insulin Sensitivity and Insulin Secretion in Obese Non-Diabetic Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine
      whether reducing subclinical inflammation lessens insulin resistance in healthy, obese
      volunteers. The study findings may lead to new strategies for preventing type 2 diabetes. In
      diabetes, blood sugar is higher than normal and can result in serious medical problems, such
      as blindness and kidney failure. People with subclinical inflammation-inflammation that does
      not produce symptoms, such as fever, pain, or skin redness-are at increased risk for
      diabetes. Although the reasons for this are not completely understood, it is known that
      subclinical inflammation exacerbates insulin resistance, which is a cause of diabetes.
      Insulin is a hormone that helps control blood sugar, and when it does not work properly, the
      condition is known as insulin resistance.

      Normal, healthy volunteers between 18 and 45 years old with a body mass index of at least 30
      kg/m2 and who have subclinical inflammation (determined by blood tests) may be eligible for
      this study. Candidates must be non-smokers and must not have an alcohol or drug problem.
      Candidates will be screened with a medical history and physical examination,
      electrocardiogram, and blood and urine tests. Participants will maintain a standard diet and
      undergo tests and procedures during a 14-day inpatient stay at the Phoenix Indian Medical
      Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In healthy subjects, low-grade inflammation, as measured by serum levels of cytokines or
      acute phase proteins, is positively associated with adiposity. Recent studies indicate that
      chronic low-grade inflammation in non-diabetic individuals may cause decline in insulin
      sensitivity and increases the risk of developing type 2 diabetes. It has been proposed that
      reduction of low-grade inflammation may reduce the risk of development of type 2 diabetes. In
      agreement with this hypothesis, the class of anti-inflammatory drugs called salicylates (such
      as aspirin) that influence a specific anti-inflammatory pathway have been found to decrease
      plasma glucose levels and increase insulin sensitivity in rodents as well as people with type
      2 diabetes.

      In the present study, we propose testing whether administration of the anti-inflammatory drug
      Salsalate improves insulin sensitivity in obese non-diabetic individuals and whether this
      improvement is related with a decrease in serum markers of inflammation. Subjects will be
      randomly assigned to two treatment groups: placebo or Salsalate (3g/d). An oral glucose
      tolerance test and a combined euglycemic/hyperglycemic clamp to assess insulin sensitivity
      and insulin secretion will be performed before and after seven days of treatment. Results of
      this study may help to identify novel strategies to prevent type 2 diabetes in high-risk
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fasting Plasma Glucose Concentration</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp</measure>
    <time_frame>last 40 min of clamp</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Salsalate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salsalate (3g/day) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>The intervention was salsalate (3g/day) for 7 days.</description>
    <arm_group_label>Salsalate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical placebo for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age: Greater than 18 and less than 45 years.

        Number: 44 completed studies (22 placebo, 22 Salsalate).

        Sex: 22 Males and 22 Females.

        BMI: Greater than or equal to 30 kg.m(2)

        EXCLUSION CRITERIA:

          -  Age below 18 or above 45 years to minimize the risk of glucose clamp.

          -  Diabetes mellitus (as per 75 g OGTT, WHO 1999 criteria)

          -  Cardiovascular disease including: abnormal EKG, personal history of coronary heart
             disease;symptomatic angina pectoris or cardiac insufficiency as defined by NYHA;
             classification as functional class III or IV.

          -  Systolic blood pressure greater than 160mmHG and/or diastolic blood pressure greater
             than 100 mmHg and/or on antihypertensive therapy or resting heart rate greater than 90
             bpm.

          -  Hematological disorder, including prolonged prothrombin time (normal range 10.9-12.9
             sec) and partial thromboplastin time (24-36 sec) and thrombocytopenia (less than
             150,000 mm(3)).

          -  Respiratory disease (including influenza, asthma)

          -  Allergies (including hay fever)

          -  Gastrointestinal (including peptic ulcer), hepatic or renal disease (ALT and AST
             greater than 3-fold above upper limit of normal range, creatinine greater than 1.3
             mg/dl).

          -  Alcoholism, alcohol-induced autonomic neuropathy.

          -  Any endocrinological disorder, including hypopituitarism/pituitary dysfunctions or
             lesions, hypo/hyperthyroidism, insulinoma.

          -  CNS disease

          -  Psychosis or personal history of any psychiatric disorder.

          -  Taking medications within one month prior to beginning the study, including
             medications known to have pharmacological interactions with salicylates or that may
             affect insulin sensitivity and secretion (including salicylates, COX 1 and COX 2
             inhibitors, warfarin, Beta-Blockers, phenothiazines, antidepressants, antiarrhythmic
             drugs, antimuscarinic drugs).

          -  Acute inflammation as assessed by history, physical and laboratory examination
             (subjects with C-reactive protein 2 standard deviations above the population mean will
             not be admitted). The population mean was calculated from subjects admitted at our
             research unit.

          -  Pregnant or lactating females or females on hormonal contraceptives.

          -  History of metabolic acidosis.

          -  Allergy to aspirin, other salicylates, or bleeding diathesis or currently on oral
             anticoagulants.

          -  Any current viral illness.

          -  Active cancer within 5 years prior to screening for the study.

          -  Positive urine drug screening test.

          -  Inability to provide informed consent.

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bogardus Clifton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institues of Diabetes and Digestive and Kidney Disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIDDK, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <reference>
    <citation>Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001 Jul;9(7):414-7.</citation>
    <PMID>11445664</PMID>
  </reference>
  <reference>
    <citation>Pratley RE, Wilson C, Bogardus C. Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender. Obes Res. 1995 Nov;3(6):563-71.</citation>
    <PMID>8653533</PMID>
  </reference>
  <reference>
    <citation>Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998 Oct;41(10):1241-8. Review.</citation>
    <PMID>9794114</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>December 29, 2010</results_first_submitted>
  <results_first_submitted_qc>January 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Clifton Bogardus</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Salsalate</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Diabetes</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment location: clinical research unit at the NIDKK (Phoenix, AZ, USA)</recruitment_details>
      <pre_assignment_details>Upon admission, all participants were placed on a weight maintaining diet (containing 50% of energy as carbohydrate, 30% as fat and 20% as protein). Body composition was measured by dual-energy x-ray absorptiometry. At least 3 days after admission and after a 12 h overnight fast a 2-h 75 g OGTT was performed to exclude diabetes.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Salsalate</title>
          <description>The intervention was salsalate (3g/day) for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>toothache</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>indigestion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chest pain</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>minor infection</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor venous access</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>anaemia or excess drop in glycaemia</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Error in data records</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Salsalate</title>
          <description>Salsalate (3g/day) for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical placebo for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="7"/>
                    <measurement group_id="B2" value="33" spread="8"/>
                    <measurement group_id="B3" value="31" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="5"/>
                    <measurement group_id="B2" value="38" spread="6"/>
                    <measurement group_id="B3" value="37.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Fat</title>
          <units>% body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="6"/>
                    <measurement group_id="B2" value="38" spread="7"/>
                    <measurement group_id="B3" value="38" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>mmol/l</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.11" spread="0.33"/>
                    <measurement group_id="B2" value="5.06" spread="0.33"/>
                    <measurement group_id="B3" value="5.09" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hour plasma glucose</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.67" spread="1.17"/>
                    <measurement group_id="B2" value="6.61" spread="1.83"/>
                    <measurement group_id="B3" value="6.64" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma insulin</title>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="56" upper_limit="104"/>
                    <measurement group_id="B2" value="63" lower_limit="49" upper_limit="90"/>
                    <measurement group_id="B3" value="76" lower_limit="49" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Basal EGP</title>
          <units>micro-mol/(kg*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="2"/>
                    <measurement group_id="B2" value="11" spread="2"/>
                    <measurement group_id="B3" value="10.5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clamp R_d</title>
          <units>micro-mol/(kg*min)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="B2" value="16" lower_limit="13" upper_limit="20"/>
                    <measurement group_id="B3" value="14" lower_limit="11" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fasting Plasma Glucose Concentration</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate</title>
            <description>Salsalate (3g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose Concentration</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="6.5"/>
                    <measurement group_id="O2" value="0.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp</title>
        <time_frame>last 40 min of clamp</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate</title>
            <description>Salsalate (3g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Average Serum Insulin Concentration During the Last 40 Min of Clamp</title>
          <units>l/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.21"/>
                    <measurement group_id="O2" value="-0.06" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Salsalate</title>
          <description>Salsalate (3g/day) for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical placebo for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Krakoff, M.D./National Institute of Diabetes and Digestive and Kidney Diseases</name_or_title>
      <organization>National Institutes of Health</organization>
      <phone>6022005217</phone>
      <email>jkrakoff@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

